SCHEMBL877415

SCHEMBL877415

COc1ccc2c(=O)n(CCC(Sc3ccc(-c4ccc(OC)c(OC)c4)cc3)C(=O)O)nnc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR139 Q6DWJ6 6/20 0.45
NPSR1 Q6W5P4 1/20 0.44
MMP2 P08253 5/20 0.42
MMP9 P14780 5/20 0.42
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
HSD17B10 Q99714 1/20 0.42
RXFP1 Q9HBX9 1/20 0.42
MMP3 P08254 3/20 0.41
MMP13 P45452 3/20 0.41
MMP1 P03956 2/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
PTGES O14684 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PPARG P37231 3/20 0.39
PPARA Q07869 3/20 0.39
ALOX5 P09917 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL875077 0.93 GPR139 (0.51) GPR139NPSR1MMP2MMP9ALDH1A1
SCHEMBL877105 0.93 GPR139 (0.43) GPR139NPSR1MMP2MMP9ALDH1A1
SCHEMBL874630 0.90 MMP2 (0.47) GPR139NPSR1MMP2MMP9ALDH1A1
SCHEMBL878203 0.89 GPR139 (0.46) GPR139NPSR1MMP2MMP9ALDH1A1
SCHEMBL875104 0.89 GPR139 (0.45) GPR139NPSR1MMP2MMP9ALDH1A1
SCHEMBL15733169 0.88 GPR139 (0.43) GPR139NPSR1MMP2MMP9ALDH1A1
SCHEMBL877286 0.88 GPR139 (0.43) GPR139NPSR1MMP2MMP9ALDH1A1
SCHEMBL878291 0.87 GPR139 (0.55) GPR139NPSR1MMP2MMP9ALDH1A1
SCHEMBL874950 0.87 GPR139 (0.55) GPR139MMP2MMP9ALDH1A1MMP3
SCHEMBL874260 0.87 GPR139 (0.43) GPR139NPSR1MMP2MMP9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2014-05-29 US claimed
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2014-05-29 US disclosed
EP-2619185-A1 MATRIX METALLOPROTEINASE INHIBITORS Ranbaxy Laboratories Limited (IN) 2013-07-31 EP disclosed
WO-2012038942-A1 MATRIX METALLOPROTEINASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140148459-A1 MATRIX METALLOPROTEINASE INHIBITORS MMP9, MMP12, MMP10 GPR139 2694/4885NPSR1 903/4885MMP2 17/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.